Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05079399 · ClinicalTrials.gov registry record
Biomarker of Diabetic Retinopathy
A clinical trial of Diabetic Retinopathy, sponsored by Indiana University.
- Recruiting
- Registry status
- 192
- Enrollment target
- 3
- Study locations
NCT05079399 is a study of Diabetic Retinopathy that is actively recruiting participants, run by Indiana University. The registered enrollment target is 192 participants, below the 1,673-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (89% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT05079399, a study of Diabetic Retinopathy, is actively recruiting participants, sponsored by Indiana University.
- RECRUITING
- Registry status
- 192 participants
- Enrollment target
- 3
- Study locations
Study Summary
Diabetic retinopathy (DR) is a complication of diabetes in which blood vessels supplying blood to the back of the eye (retina) are dysfunctional. This can lead to an improper supply of oxygen and nutrients to the retinal tissue, or it may trigger the formation of new blood vessels in response to the oxygen/nutrient deficiency. Ultimately affecting the normal vision. There is no known marker that will provide information on the health status of retinal blood vessels. Using highly specialized cells in the blood, this study will try to discover a marker of DR.
Conditions Studied
Interventions
- OTHER Blood draw
Study Locations (3)
Indiana
- Spring Mill Clinic - Carmel
- Eskenazi Eye Clinic - Indianapolis
- Glick Eye Institute - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2022-01-01 |
| Est. Completion | 2026-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05079399
The ClinicalTrials.gov registry entry for NCT05079399 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,673-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (89% lower). The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Retinopathy appearing as the primary indexed condition, and to 1 intervention - of which Blood draw is the first listed.
NCT05079399 reports 3 study locations spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT05079399 about?
NCT05079399 is a clinical study titled "Biomarker of Diabetic Retinopathy". Diabetic retinopathy (DR) is a complication of diabetes in which blood vessels supplying blood to the back of the eye (retina) are dysfunctional. This can lead to an improper supply of oxygen and nutrients to the retinal tissue, or it may trigger the formation of new blood vessels in response to the...
What is the current status of trial NCT05079399?
This trial is currently recruiting. The enrollment target is 192 participants. The study started on 2022-01-01. Estimated completion is 2026-06-30.
What conditions does trial NCT05079399 study?
This clinical trial studies the following conditions: Diabetic Retinopathy.
What interventions are being tested in trial NCT05079399?
The interventions under investigation include: Blood draw (OTHER).
Who is sponsoring clinical trial NCT05079399?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05079399 being conducted?
This trial has 3 study locations across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Retinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fenofibrate for Prevention of DR Worsening
RECRUITING · Phase 3
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
RECRUITING
-
Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities
RECRUITING · NA
-
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
RECRUITING · Phase 2
-
Human iPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.